Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines
| Autor: | Hans Petter Eikesdal, Per Eystein Lønning, Stian Knappskog, Synnøve Yndestad, Eilin Austreid, Ida Svanberg |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Indazoles Indoles Anthracycline Cell Survival Estrogen receptor AKT1 Breast Neoplasms Mice SCID doxorubicin 03 medical and health sciences breast cancer 0302 clinical medicine Breast cancer Mice Inbred NOD Cell Line Tumor Internal medicine medicine Animals Humans Cytotoxic T cell Anthracyclines Doxorubicin skin and connective tissue diseases Protein kinase B Antibiotics Antineoplastic drug resistance business.industry Akt medicine.disease Xenograft Model Antitumor Assays Enzyme Activation Gene Expression Regulation Neoplastic 030104 developmental biology Endocrinology Receptors Estrogen Oncology Drug Resistance Neoplasm 030220 oncology & carcinogenesis MCF-7 Cells Cancer research Female business Proto-Oncogene Proteins c-akt Research Paper estrogen receptor Epirubicin medicine.drug |
| Zdroj: | Oncotarget OncoTarget 41227-41241 |
| ISSN: | 1949-2553 |
| Popis: | Anthracyclines are key components of human breast cancer chemotherapy. Here, we explored the role of Akt signaling in anthracycline resistance. The antitumor activity of doxorubicin and Akt inhibitor A-443654 alone or combined was examined in estrogen receptor (ER) positive and negative human breast cancer cell lines. Further, we examined mRNA changes induced by anthracyclines in locally advanced breast cancers biopsied before and after treatment in two clinical trials. Doxorubicin increased Akt phosphorylation in ER positive MCF7 and T47D cell lines, with no effect in ER negative MDA-MB231 breast cancer cells. A-443654 was significantly more cytotoxic in doxorubicin-resistant compared to doxorubicin-naïve MCF7. This difference was not observed in MDA-MB231. Among 24 patients, AKT1 gene expression increased 24 hrs after the initial epirubicin exposure in ER positive tumors responding to therapy (n=6), as compared to ER positive non-responders (n=7) or ER negative tumors (n=11). In contrast, AKT1 mRNA changes after 16 weeks of doxorubicin were unrelated to clinical response and ER status (n=30). In conclusion, rapid Akt activation was observed in ER positive breast cancers which responded to anthracyclines. Increased cytotoxicity of A-443654 in doxorubicinresistant MCF7 cells indicates a possible role for Akt inhibitors in ER positive breast cancers where chemoresistance evolves. publishedVersion |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|